Redeye remains positive to Nekkar’s on the back of a Q4’24 report that beat our forecast, mainly dri...
Redeye updates its estimates and valuation after OEM’s Q4 2024 report.
Redeye strengthens its positive view of Avensia following an overall solid Q4 report.
We cut underlying '25e-'26e EBITA by 5-4%, mainly in service units Positioned to accelerate M&A in m...
Medicinteknikbolaget iZafe Group rapporterade i linje med vår prognos.
Redeye comments on Integrum’s directed share issue and we adjust our fair value range per the new nu...
Weaker Q4 than we expected, on higher opex, but ACV was strong We cut '25e-'26e adj.
Redeye has updated its estimates and provided commentary on the latest developments at Starbreeze.
Sales +3%, adj. EBITA +34%, +4% org. growth '25e-'26e EBITA estimates to increase by 5-10% Share to ...
Under fjärde kvartalet levererade Botnia sin första guldtacka till kund.
Sales in line with cons, adj. EBITA -7% vs cons Consensus EBITA estimate revisions slightly negative...
Sales +0%, EBIT +31% vs. ABGSCe, beat driven by FX revaluations Underlying EBIT in line with our exp...
Raketech’s Q4-results were in line with the preannouncement from February 4 where the company report...
Redeye provides an initial comment on the Q4 2024 report from Cheffelo, which was in line with annou...
External manufacturing and Artscape raise growth to 6% y-o-y DTC grew 100% y-o-y in 2024, more to co...
Redeye provides its initial take on Surgical Science’s Q4 2024 report, which featured decent top lin...
Vaisala’s 2024 ended on a strong note as was expected after January’s positive profit warning.
Redeye provides an update following Truecaller’s Q4 2024 report, which exceeded expectations across ...
Redeye states CoinShares Q4 2024 report exceeded Redeye Research estimates (RRe) across all segments...
Redeye concludes that Smart Eye's Q4 2024 report was even better than it looked at first sight.